New TB Drug Regimen Shows Promise for Shorter Treatment

A new combination of drugs could significantly shorten treatment for tuberculosis (TB). This follows positive results from a Phase 2 clinical trial in South Africa. The trial tested an experimental drug, sorfequiline, alongside two others: pretomanid and linezolid. Researchers conducted the study in people with drug-sensitive TB, the most common form of the disease. A Phase 2 trial primarily assesses a treatment's effectiveness and appropriate dosage. Current TB treatment typically requires patients to take antibiotics for at least six months. A shorter, effective regimen would make it easier for patients to complete their full course of medicine. This improves individual health outcomes and helps control the spread of TB. Further large-scale trials are needed to confirm these findings before the regimen can be approved for widespread use.